The thing that created the conditions that made 2020 so awful for so many – the coronavirus pandemic – also created the conditions for tech to stage an impressive rally. The three promising tech stocks highlighted in today’s article, however, did not participate in that rally. As a result, these underperforming stocks “still trade at levels that leave room for huge growth” and “could turn things around and deliver fantastic returns to shareholders in 2021.” For these three stocks, CLICK HERE.
The coronavirus pandemic is surging. The economy is in a precarious state. The outcome of the presidential election may well be contested. International tensions are rising. And the author of today’s article advises that “These risks are presenting a once-in-a-lifetime chance to turbocharge your investment gains.” How? By trading options, which he argues is easier than many investors think. For more on how you can use options to realize supersized gains in a short period of time in the current market environment, CLICK HERE.
Dr. David Nierengarten, Managing Director and Head of Healthcare Equity Research at Wedbush Securities, sees potential in many biotech stocks, especially in the genetic-medicine and oncology spaces. For several specific genetic-medicine and oncology names that Nierengarten is particularly bullish on – including one company with a gene therapy for a rare retinal disease that causes significant vision loss (and sometimes complete blindness) in males – CLICK HERE.
“With all of the hype about the race to develop coronavirus vaccines, it’s not surprising that short-sellers have piled on some of the stocks of biotechs with COVID-19 vaccine candidates,” acknowledges the author of today’s article. He further points out, however, that “if these companies have good news, there could be a short-squeeze scenario where the stocks skyrocket as short-sellers scramble to cover their positions.” So which coronavirus vaccine stocks are the most heavily shorted right now, potentially setting up big opportunities for investors? CLICK HERE.
“As an investor, this sets up a great opportunity to get in on the ground floor and earn triple-digit profits in short order,” advises the author of today’s article in regards to a little-known segment of the thriving biotech industry that appears poised for a massive breakout to the upside in the coming months. Just what is this biotech segment that’s deserving of attention? CLICK HERE.
In regards to the biotech sector, the author of today’s article advises that “it makes sense to keep an eye on this general area of the market as it is likely to play an increasingly significant role not just in the fight against Covid-19 but also in the war on cancer, the battle against rare diseases, and increasingly on more common diseases where traditional treatments are running into limitations.” For what he sees as an ideal way to invest in biotech – and his recommendation on when to buy – CLICK HERE.
Today’s article highlights two cheap healthcare stocks that, while having suffered so far this year, have growth drivers at hand that should set them up for rebounds going forward: “The first of these great deals, a pharmaceutical company, has a blockbuster on the market, a newer drug with growing sales, and possible drug approvals in the coming months. And the second great deal is a diagnostics player with a huge opportunity in cancer screening.” For more, CLICK HERE.
While analysts at Goldman Sachs believe that the S&P 500 will rise to 3,000 by the end of the year, they also caution that, despite the market having rallied in recent days, more pain lies ahead in the coming weeks and that the market has not hit its coronavirus-induced bottom yet. When can market participants feel confident that the market has indeed hit bottom? The analysts outline three criteria that they believe must be met. CLICK HERE.
“Instead of worrying about how far share prices will fall or how widely the coronavirus will spread, think about the opportunities,” advises the author of today’s article, who proceeds to outline four opportunities he sees currently – including an opportunity for retirees who need cash from their homes. For more, CLICK HERE
How can investors – especially retired investors – beat the market without fail? The author of today’s article outlines “a simple step-by-step common sense-based strategy” to do just that, with the following caution: “What I will be presenting may not be what you are expecting, particularly if you have a narrow notion of what beating the market means. In other words, one of my primary objectives will be to expand your mind and attitudes regarding what investment performance is truly all about.” For more, CLICK HERE.